Pfizer struck a discovery collaboration with Cartography Biosciences to use Cartography’s ATLAS and SUMMIT platforms to identify tumor‑selective antigens for an undisclosed oncology indication. Financial terms include up to $65 million in near‑term payments and potential downstream milestones and royalties that could lift the deal value to roughly $865 million if multiple options are exercised. Cartography will nominate antigens using single‑cell and computational analytics; Pfizer may opt into multiple targets and will lead subsequent development. Cartography framed the pact as validation of its multi‑modal antigen‑discovery engines and said the work could yield candidates suited to multi‑specific or precision biologic modalities.